About Careers Internship MedBlogs Contact us
Medindia LOGIN REGISTER
Advertisement

High-Frequency Migraine Patients Benefit Less from New Drug

by Ramya Rachamanti on July 11, 2019 at 5:26 PM
Font : A-A+

High-Frequency Migraine Patients Benefit Less from New Drug

Newly approved drug does not seem to be effective for high-frequency migraine sufferers, according to a new review. The findings will be presented during the 61st annual scientific meeting of the American Headache Society in Philadelphia.

Clinicians at OHSU in Portland, Oregon, conducted a retrospective chart review of 28 patients who were prescribed 70 miligrams of Erenumbab per month for three months beginning in June of 2018. Each of the patients reported 25 or more headache days per month when they began the treatment.

Advertisement


Given the relatively high cost of the new antibody treatment - a list price of $6,900 - clinical care at OHSU has focused on prescribing it for patients with incapacitating and frequent migraines. They hoped to reduce the number of headaches by at least half through once-monthly self-injections.

None of the high-frequency patients achieved a 50 percent reduction in headache frequency, although six patients reported a reduction of at least 25 percent.
Advertisement

The U.S. Food and Drug Administration approved Erenumbab in May of 2018.

"In a climate where financial constraint cannot be ignored, when possible use of new medications should be tailored as specifically as possible to limit waste of a finite resource," said Juliette Preston, M.D., director of the OHSU headache center and assistant professor of medicine in the OHSU School of Medicine.

Source: Eurekalert
Advertisement

Advertisement
News A-Z
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
What's New on Medindia
Monkeypox Outbreak: What it is, How Does it Spread & the Prevention
Seasonal Allergy Medications
How to Choose the Best Eczema-Friendly Moisturizer for Children?
View all
Recommended Reading
News Archive
Date
Category
Advertisement
News Category

Medindia Newsletters Subscribe to our Free Newsletters!
Terms & Conditions and Privacy Policy.

More News on:
Drug Toxicity Migraine Clinical Trials - Different Phases of the trial Signature Drug Toxicity Headache / Cephalgia Drugs Banned in India Headache Symptom Evaluation Retinal Migraine / Ocular Migraine Menstrual Migraine Drug Induced Headache 

Most Popular on Medindia

Blood Pressure Calculator Hearing Loss Calculator The Essence of Yoga Iron Intake Calculator Selfie Addiction Calculator Drug Interaction Checker Daily Calorie Requirements Post-Nasal Drip Noscaphene (Noscapine) Diaphragmatic Hernia

Disclaimer - All information and content on this site are for information and educational purposes only. The information should not be used for either diagnosis or treatment or both for any health related problem or disease. Always seek the advice of a qualified physician for medical diagnosis and treatment. Full Disclaimer

© All Rights Reserved 1997 - 2022

This site uses cookies to deliver our services. By using our site, you acknowledge that you have read and understand our Cookie Policy, Privacy Policy, and our Terms of Use